Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CALANASDAQ:CLSNNASDAQ:RNXTOTCMKTS:SEGINYSE:TMBR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.03$0.02$0.01▼$0.50$141K-0.171,587 shs583 shsCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsRNXTRenovoRx$1.20-2.4%$1.39$0.53▼$3.29$20.24M1.0559,475 shs2,766 shsSEGISycamore Entertainment Group$0.00$0.00$0.00▼$0.01$1.48M47.661.21 million shs920,350 shsTMBRTimber Pharmaceuticals$1.87$0.32▼$3.39$1.21M0.03511,937 shs26,307 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences0.00%-49.90%0.00%-16.50%-37.38%CLSNImunon0.00%0.00%0.00%0.00%0.00%RNXTRenovoRx+5.13%+6.03%-13.38%+14.95%-58.86%SEGISycamore Entertainment Group+7.69%+16.67%+7.69%+16.67%-36.36%TMBRTimber Pharmaceuticals0.00%0.00%0.00%0.00%-75.81%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AN/AN/AN/ARNXTRenovoRx0.6164 of 5 stars3.33.00.00.00.00.00.0SEGISycamore Entertainment GroupN/AN/AN/AN/AN/AN/AN/AN/ATMBRTimber PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera BiosciencesN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/ARNXTRenovoRx2.67Moderate Buy$8.50608.33% UpsideSEGISycamore Entertainment GroupN/AN/AN/AN/ATMBRTimber Pharmaceuticals2.00HoldN/AN/ACurrent Analyst RatingsLatest CALA, SEGI, TMBR, CLSN, and RNXT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/2/2024RNXTRenovoRxAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$4.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera Biosciences$9.75M0.01N/AN/A($0.40) per share-0.07CLSNImunon$500K0.00N/AN/A$9.66 per share0.00RNXTRenovoRxN/AN/AN/AN/A($0.28) per shareN/ASEGISycamore Entertainment GroupN/AN/AN/AN/AN/AN/ATMBRTimber Pharmaceuticals$80K0.00N/AN/A$1.79 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/ACLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/ARNXTRenovoRx-$10.23M-$1.01N/A∞N/AN/A-2,860.14%-261.49%5/20/2024 (Estimated)SEGISycamore Entertainment GroupN/AN/A0.00∞N/AN/AN/AN/AN/ATMBRTimber Pharmaceuticals-$19.38MN/A0.00N/AN/AN/A-511.45%-180.93%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/ARNXTRenovoRxN/AN/AN/AN/AN/ASEGISycamore Entertainment GroupN/AN/AN/AN/AN/ATMBRTimber PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALACalithera BiosciencesN/AN/AN/ACLSNImunon0.136.526.52RNXTRenovoRxN/A1.161.16SEGISycamore Entertainment GroupN/AN/AN/ATMBRTimber PharmaceuticalsN/A0.500.50OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/ACLSNImunon12.97%RNXTRenovoRx3.10%SEGISycamore Entertainment GroupN/ATMBRTimber Pharmaceuticals3.62%Insider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%CLSNImunon4.66%RNXTRenovoRx9.00%SEGISycamore Entertainment Group75.50%TMBRTimber Pharmaceuticals1.61%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences84.87 million4.55 millionNot OptionableCLSNImunon277.10 million6.77 millionOptionableRNXTRenovoRx816.87 million15.35 millionNot OptionableSEGISycamore Entertainment GroupN/A2.46 billion603.35 millionNot OptionableTMBRTimber Pharmaceuticals93.43 million3.38 millionNot OptionableCALA, SEGI, TMBR, CLSN, and RNXT HeadlinesSourceHeadlineTimber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meetingbusinesswire.com - March 10 at 6:15 PMTimber Pharmaceuticals Announces Official Name Changemsn.com - January 28 at 10:14 AMTimber Pharmaceuticals Inc (TMBRQ)uk.investing.com - January 13 at 12:47 PMTimber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Marketfinance.yahoo.com - November 29 at 10:13 PMNYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)finance.yahoo.com - November 29 at 12:12 PMTimber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE Americantmcnet.com - November 28 at 5:55 PMTimber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE Americanfinance.yahoo.com - November 28 at 5:55 PMMVST, FBIO and VTVT among mid-day moversseekingalpha.com - November 21 at 6:44 PMTimber Pharmaceuticals files for Chapter 11 in wake of failed mergermsn.com - November 17 at 8:30 PMTimber Pharma slips ahead of shareholder vote on mergermsn.com - November 16 at 12:58 PMTimber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliancefinance.yahoo.com - September 18 at 6:22 PMHC Wainwright Downgrades Timber Pharmaceuticals247wallst.com - August 29 at 5:22 PMHC Wainwright & Co. Downgrades Timber Pharmaceuticals (TMBR)msn.com - August 28 at 10:33 PMTimber Pharmaceuticals rockets as it agrees to a takeoverthepharmaletter.com - August 21 at 4:33 PMTMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to Shareholdersbenzinga.com - August 21 at 4:33 PMDow Tumbles Over 100 Points; Timber Pharmaceuticals Shares Spike Highermarkets.businessinsider.com - August 21 at 4:33 PMTimber to be taken private by LEO Pharma, stock soars 100%msn.com - August 21 at 4:33 PMWhy Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today?investorplace.com - August 21 at 12:01 PMUS Stocks Mostly Higher; Nasdaq Jumps 100 Pointsmarkets.businessinsider.com - August 21 at 11:31 AMTimber Pharmaceuticals Shares Soar on Takeover by LEO Pharmamarketwatch.com - August 21 at 11:31 AMWhy Timber Pharmaceuticals Stock Is Skyrocketing Todaybenzinga.com - August 21 at 11:31 AMLEO Pharma Signs Agreement to Acquire Timber Pharmaceuticalsfinance.yahoo.com - August 21 at 11:31 AMTimber Pharmaceuticals to be Acquired by LEO Pharmafinance.yahoo.com - August 21 at 11:31 AMTimber Pharmaceuticals Inc Ordinary Sharesmorningstar.com - August 15 at 5:22 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCalithera BiosciencesNASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.RenovoRxNASDAQ:RNXTRenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.Sycamore Entertainment GroupOTCMKTS:SEGISycamore Entertainment Group, Inc., a diversified entertainment company, which specializes in the acquisition, marketing, and worldwide distribution of feature-length motion pictures. The company is based in Seattle, Washington.Timber PharmaceuticalsNYSE:TMBRTimber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.